Olmesartan/Hidroclorotiazida Mabo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/Hidroclorotiazida Mabo is used within the renin‑angiotensin‑aldosterone system pathway to manage high blood pressure.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure adjunct: assists in fluid management when combined with diuretics.
• Diabetic nephropathy protection: helps slow progression of kidney damage associated with diabetes.
• Stroke prevention: contributes to long‑term risk reduction in patients with elevated blood pressure.
• Post‑myocardial infarction care: supports blood‑pressure control as part of secondary prevention.
• Resistant hypertension: provides an additional mechanism when standard therapy is insufficient.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide, a thiazide‑type diuretic, inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume. The combined actions produce additive reductions in systemic vascular resistance and extracellular fluid volume, resulting in lowered arterial pressure.

Common Side Effects

• Dizziness or light‑headedness, especially after the first doses.
• Headache.
• Fatigue or mild weakness.
• Increased urination.
• Electrolyte disturbances such as low potassium.
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Acute kidney injury or significant rise in serum creatinine.
• Hyperkalemia or severe electrolyte imbalance.
• Angio‑edema involving the face, lips or airway.
• Hepatic dysfunction with jaundice.
• Blood dyscrasias such as agranulocytosis or thrombocytopenia.

Before initiating therapy, consider the following precautions:

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels regularly.
• Hepatic disease: use cautiously in patients with liver impairment.
• Pregnancy: avoid use during the second and third trimesters; discuss risks with a physician.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Olmesartan/Hidroclorotiazida Mabo may interact with several medicines. Review the following categories:

Major Interactions (Avoid)

• Aliskiren: concurrent use in diabetic patients can increase risk of renal dysfunction and hyperkalemia.
• Potassium‑saving diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive risk of hypotension, hyperkalemia, and renal impairment.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.